ArticleThe Journal of antimicrobial chemotherapy2025
Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023).
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Real-World Data on the Effectiveness and Use of Intravenous Fosfomycin for the Treatment of Difficult-to-Treat Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria-A Subgroup Analysis from the FORTRESS Study.Infectious diseases and therapy · 2026Article
- Article
- When might we consider using the newer β-lactam agents as empirical therapy against presumed carbapenem-resistant gram-negative infections?JAC-antimicrobial resistance · 2026Review
- Combating Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Comparative effectiveness and safety of aztreonam-avibactam or ceftazidime-avibactam plus aztreonam versus best available therapy for severe gram-negative infections: a systematic review, meta-analysis, and trial sequential analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- HighMicrobiology spectrum · 2026Article
- Continuous Infusion of Aztreonam-Avibactam After High Loading Dose for an Infection Caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella pneumoniae.Infectious diseases and therapy · 2026Article
- [Beta-lactams and beta-lactamase inhibitors-current developments].Innere Medizin (Heidelberg, Germany) · 2025Review
- Use of Aztreonam-Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-ProducingAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesTo evaluate the in vitro activity of aztreonam/avibactam against Enterobacterales from European medical centres during the 5-year period prior to its approval for clinical use in Europe.
methodsThirty thousand seventy-four Enterobacterales isolates were consecutively collected in 2019-2023 from 19 medical centres in Eastern Europe and Mediterranean region (E-EU; n = 8074) and 27 medical centres in Western Europe (W-EU; n = 22 000) and susceptibility tested by broth microdilution. Carbapenem-resistant Enterobacterales (CRE) and isolates with elevated MICs (>4 mg/L) for aztreonam/avibactam were molecularly characterized.
resultsAztreonam/avibactam was active against 99.8% and >99.9% of Enterobacterales from E-EU and W-EU, respectively and exhibited potent activity against CRE isolates (MIC50/90, 0.25/0.5 mg/L; 99.6%/99.7% susceptible in E-EU/W-EU). Cefiderocol was active against 74.8%/87.6% of CREs from E-EU/W-EU. Ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam retained moderate activity against CRE isolates from W-EU (68.3-80.3% susceptibility) but showed limited activity against CRE isolates from E-EU (45.1-63.0% susceptible). The occurrence of carbapenemases varied markedly among the countries evaluated. In general, the MBLs predominated in E-EU and the KPCs prevailed in W-EU. Decreased susceptibility to aztreonam/avibactam was predominantly due to PBP3 alterations and production of CMY and/or CTX-M β-lactamases among Escherichia coli, and hyperexpression of ampC plus porin alterations in Enterobacter cloacae species complex and Klebsiella aerogenes.
conclusionsThe results of this investigation provide a valuable benchmark for monitoring the in vitro activity of aztreonam/avibactam after its clinical approval in Europe and emphasizes the importance of comprehensive surveillance programmes to monitor the emergence of high-risk clones and resistance mechanisms to newly approved antimicrobial agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.